9 / 49
Presented by: Keith T. Flaherty, MD
1. Hauschild A, et al.
Lancet
2012;380:358; updated in
J Clin Oncol.
2013 (suppl) [abstract 9013]; 2. McArthur GA, et al.
Lancet Oncol
. 2014;15:323-332; 3. Flaherty KT, et al.
N Engl J Med.
2012;367:107-114; 4. Long GV, et al.
Lancet.
2015;386:444-451; 5.
Robert C, et al.
N Engl J Med.
2015;372:30-39;
6. Atkinson V, et al. SMR. 2015.
BRAFi (dabrafenib)
PFS HR, 0.37
vs DTIC
1
Hyperproliferative skin AEs
BRAFi (vemurafenib)
PFS HR, 0.38
vs DTIC
2
Hyperproliferative skin AEs
MEKi (trametinib)
PFS HR, 0.45
vs chemotherapy
3
pERK
Proliferation, Survival,
Invasion, Metastasis
RAS
MEK
BRAFi + MEKi ph 3 studies
BRAF
mutBRAF
Dabrafenib + trametinib
PFS HR, 0.67
vs dabrafenib
4
OS HR, 0.71
vs dabrafenib
4
PFS HR, 0.56
vs vemurafenib
5
OS HR, 0.69
vs vemurafenib
5
Vemurafenib + cobimetinib
PFS HR, 0.58
vs vemurafenib
6
OS HR, 0.70
vs vemurafenib
6
Decreased hyperproliferative skin AEs
4,5,6
AE, adverse event; BRAF, v-Raf murine sarcoma viral oncogene homolog B; BRAFi, BRAF inhibitor; DTIC, dacarbazine; HR, hazard ratio; MEK, mitogen-activated protein kinase kinase; MEKi, MEK inhibitor; mut, mutant; OS, overall
survival; pERK, phospho-extracellular signal-regulated kinase; PFS, progression-free survival; ph, phase.
NP4: 1606042435
encorafenib
Encorafenib + binimetinib